Abstract:e18620 Background: Breast cancer (BC) is the most commonly diagnosed cancer in women. Despite overall improvements in BC outcomes, African American (AA) women are 41% more likely to die from BC. Causation of the disparity gap is multifactorial including less access to quality treatment, such as clinical trials (CTs). AA patients (pts) account for 12% of new BC cases in the United States, but constituted only 3% of the participants in the BC CTs that led to U.S. Food and Drug Administration approvals from 2008-2018. Lack of diverse participation on CTs does not allow the broad applicability of the results. As part of the "Bringing Quality Care Training to Komen’s African American Health Equity Initiative" in collaboration with ASCO, the Cardinal Bernardin Cancer Center (CBCC) examined the process for CT selection in order to increase opportunities for AA BC pts to participate in CTs. Methods: The CBCC team, comprised of social worker, breast program coordinator, medical oncology, and director of outreach developed process maps for CT selection, analyzed the BC CT content, and identified gaps relative to the pt population for industry and cooperative group CTs. The team surveyed faculty on reasons for not enrolling pts in CTs and assessed the demographics of the CT participants. Tumor registry identified BC pts by sex, race, ethnicity, phenotype and stage. Results: The CBCC treated 283 new BC cases in 2021. AA patients made up 15% (n = 22), 18% (n = 9), and 23% (n = 5) of stages I, II/III, and IV respectively. Fifteen percent were triple negative BC. Review of Velos demonstrated that CBCC enrolled 13 BC pts onto 2 BC drug CTs in 2021. We projected the need for CT selection based upon stage at diagnoses and tumor biology. We identified the following gaps in the breast oncology CT portfolio: non-competing neo-adjuvant CTs; adjuvant endocrine, HER2-targeted and triple negative CTs; and metastatic endocrine and HER2-targeted CTs. Faculty surveys demonstrated perceptions for not enrolling pts in CTs including low health literacy amongst pts, pt ineligibility, lack of institutional support, pt mistrust, language barriers, lack of time, and pt co-morbidities. Overall, pts were more likely to participate in cancer CTs if they were non-Hispanic white, privately insured, married and 60-69 years old. Conclusions: CTs lead to treatment advancements at faster rates with concurrent mortality reductions in the cancer population. It is necessary to increase representation in CT to address health equity. This requires intentional detail to the CT development and implementation process. Our study identified a number of factors, including structural, clinical, and attitudinal barriers on the part of the physician that impair enrollment. Institutions need to construct CT portfolios to ensure that it reflects the pt population that it serves. Further studies need to include the pt experience in CT participation.

[Challenges to International Collaborative Clinical Research and Approval Disparities]

Current status of therapy for breast cancer worldwide and in Japan

Disparities in gynecologic oncology clinical trial availability in the United States: A state-level analysis.

Guidelines for clinical evaluation of anti‐cancer drugs

Transitional dynamics in oncology clinical trials: evaluating the impact of Clinical Trials Act on cooperative groups

[Current Status and Issues in Drug Development for Rare Cancers]

Current Challenges of Asian National Children's Cancer Study Groups on Behalf of Asian Pediatric Hematology and Oncology Group

Next-Generation Clinical Trials and Research with Successful Collaborations

An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China

Cell and gene therapy approvals in Japan and the need for international harmonization

Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology

Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan

A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients

Emerging ethnic differences in lung cancer therapy

Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan

Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial

Influence of Expedited Programs in the United States on Oncology Drug Development in Japan

Addressing the clinical trial selection process to improve representation by African American patients with breast cancer in cancer clinical trials.

Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers

A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib